Brief: Lineage Cell Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results

Lineage Cell Therapeutics

09/03/2023 21:20

March 9 (Reuters) - Lineage Cell Therapeutics Inc
 LCTX.A :
    * LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL
YEAR
2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
    * CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES TOTALED
$57.9
MILLION AS OF DEC 31, 2022, TO SUPPORT OPERATIONS INTO Q3 2024
    * QTRLY NET LOSS ATTRIBUTABLE TO LINEAGE FOR 3 MONTHS ENDED
DECEMBER 31, 2022 WAS $6.4 MILLION, OR $0.03 PER SHARE
    * Q4 EARNINGS PER SHARE VIEW $-0.04 -- REFINITIV IBES DATA
    * TOTAL REVENUES FOR THREE MONTHS ENDED DECEMBER 31, 2022
WERE
APPROXIMATELY $1.9 MILLION
    * Q4 REVENUE VIEW $2.6 MILLION -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw1FCT68a 
Further company coverage:  LCTX.A 

 ((Reuters.Briefs@thomsonreuters.com;))